生命科学资讯

Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b

NMD flunks rare disease trial but flexes secondary data to accelerate program

Quest launches residual disease blood test for multiple myeloma

How Mirum is Advancing Rare Disease Care Through Strategic M&A

Novo’s CagriSema tops semaglutide in ph. 3 diabetes study

GSK gives back rights to Wave's genetic disease RNA editor

Thermo Fisher trims Massachusetts headcount with Franklin site closure

GSK plans to lay off up to 350 R&D workers across US, UK

Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health

Roche's return to RNA continues with $1.7B deal for Sanegene program

Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative

China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug

Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again

Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease

AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection

CRO Sygnature Discovery plans to send 60 UK staffers packing

Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’

Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate

Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program

Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech